Crohn's Disease Treatments

Find Crohn's Disease Treatments

Generic Name

Adalimumab

Brand Names

Adalimumab-aacf, Humira

FDA approval date: December 31, 2002

Form: Kit

What is Adalimumab-aacf (Adalimumab)?

Adalimumab-aacf is a tumor necrosis factor blocker indicated for: Rheumatoid Arthritis .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response

Who is this study for: Patients with early rheumatoid arthritis

Enrollment Status: Recruiting

Publish Date: June 17, 2026

Intervention Type: Drug

Study Drug: Methotrexate

Study Phase: Phase 3

Summary: Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure. Current treatment goals are to minimize pain, limit joint damage, and prevent loss of function. Drugs used to treat RA include non-steroidal anti-inflammatory drugs (NSAIDS), glucocorticoids, and disease-modifying anti-rheumatic drugs (DMARDs), including biologics...

Efficacy and Safety of Standard-Dose TNF Inhibitor Plus Low-Dose Upadacitinib Versus TNF Inhibitor Intensification for Crohn's Disease With Suboptimal Response to Standard-Dose TNF Inhibitors: A Multicenter, Randomized, Controlled Trial

Enrollment Status: Recruiting

Publish Date: June 09, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with moderate-to-severe Crohn's disease who have a suboptimal response to standard-dose TNFi therapy. Eligible participants are adults with active Crohn's disease receiving stan...

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Enrollment Status: Recruiting

Publish Date: June 02, 2026

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

Summary: This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

View All Clinical Trials